These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 4442251)

  • 1. Letter: FDA drug bulletin.
    Schmidt AM
    Clin Toxicol; 1974; 7(5):551-7. PubMed ID: 4442251
    [No Abstract]   [Full Text] [Related]  

  • 2. Proposed changes in Food and Drug Administration regulations concerning formula products and vitamin-mineral dietary supplements for infants.
    Pediatrics; 1967 Nov; 40(5):916-22. PubMed ID: 6075669
    [No Abstract]   [Full Text] [Related]  

  • 3. Nutritional regulations and legislation--past developments, future implications.
    Harper AE
    J Am Diet Assoc; 1977 Dec; 71(6):601-9. PubMed ID: 336669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safeguarding supplements. US Pharmacopeia sets quality standards for FDA and the supplement industry.
    Corken A
    J Am Diet Assoc; 1992 Dec; 92(12):1461. PubMed ID: 1452957
    [No Abstract]   [Full Text] [Related]  

  • 5. Plugs for drugs.
    Masson A; Rubin PH
    Regulation; 1986; 10(1):37-43, 53. PubMed ID: 10280556
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA Export Reform and Enhancement Act of 1996: the FDA's new extraterritorial authority over labeling and promotional practices.
    Helmanis AM
    Food Drug Law J; 1996; 51(4):631-5. PubMed ID: 11797732
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulating vitamins and minerals.
    Hopkins H
    FDA Consum; 1976; 10(6):10-1. PubMed ID: 829226
    [No Abstract]   [Full Text] [Related]  

  • 8. Psychiatric drugs and trends; new regulations on vitamins and minerals.
    Dembicki EL
    J Psychiatr Nurs Ment Health Serv; 1974; 12(2):43-5. PubMed ID: 4362712
    [No Abstract]   [Full Text] [Related]  

  • 9. Dealing with drug advertising. The FDA can't always enforce the rules on misleading ads.
    Atkinson HG
    Health News; 2003 Feb; 9(2):5. PubMed ID: 12632541
    [No Abstract]   [Full Text] [Related]  

  • 10. Stoning a dead bird: advertising limits on approved new drugs.
    Strobos J
    Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
    [No Abstract]   [Full Text] [Related]  

  • 11. A global view of the First Amendment constraints of FDA.
    Carver KH
    Food Drug Law J; 2008; 63(1):151-215. PubMed ID: 18561459
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA acts on estrogen, progestin labeling.
    FDA Consum; 1977 Nov; 11(9):3. PubMed ID: 10305006
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA tightens rules on advertising.
    Josefson D
    BMJ; 1997 Aug; 315(7106):447. PubMed ID: 9284658
    [No Abstract]   [Full Text] [Related]  

  • 14. New restrictions on health claims for dietary supplements.
    King AB
    Nutrition; 1994; 10(4):358-9. PubMed ID: 8000160
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA in hot water again over cost of proposed drug labeling rule.
    Demkovich LE
    Natl J (Wash); 1979 Sep; 11(38):1568-70. PubMed ID: 10243426
    [No Abstract]   [Full Text] [Related]  

  • 16. Off label drug promotion.
    Body Posit; 1998 Oct; 11(10):11. PubMed ID: 11365909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL; Katz KA
    Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The meaning of FDA approval.
    Fischer RG
    Pediatr Nurs; 1987; 13(5):360. PubMed ID: 3658520
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA commissioner discusses issues of concern to hospital pharmacists. Interview by William A. Zellmer.
    Goyan JE
    Am J Hosp Pharm; 1980 May; 37(5):738-40 contd. PubMed ID: 7386484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.